Background: In recent decades, extensive resources have been invested to develop cellular, molecular and genomic technologies with clinical applications that span the continuum of cancer care. Methods: In December 2006, the National Cancer Institute sponsored the first workshop to uniquely examine the state of health services research on cancer-related cellular, molecular and genomic technologies and identify challenges and priorities for expanding the evidence base on their effectiveness in routine care. Results: This article summarizes the workshop outcomes, which included development of a comprehensive research agenda that incorporates health and safety endpoints, utilization patterns, patient and provider preferences, quality of care and access, disparities, economics and decision modeling, trends in cancer outcomes, and health-related quality of life among target populations. Conclusions: Ultimately, the successful adoption of useful technologies will depend on understanding and influencing the patient, provider, health care system and societal factors that contribute to their uptake and effectiveness in ‘real-world’ settings.

Keywords:
Genomics, Health services research, Emerging technologies, Translational research
1.
Moses H, Dorsey ER, Matheson DH, Thier SO: Financial anatomy of biomedical research. JAMA 2005;294:1333–1342.
2.
Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, et al: Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer – a plan to move forward. Clin Cancer Res 2006;12:3661–3697.
3.
Deverka PA, Doksum T, Carlson RJ: Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges. Clin Pharmacol Ther 2007;82:427–434.
4.
American Society of Clinical Oncology: American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397–2406.
5.
Mueller NE, Birmann BM, Parsonnet J, Schiffman MH, Stuver SO: Infectious agents; in Schottenfeld D, Fraumeni JF (eds): Cancer Epidemiology and Prevention. New York, Oxford University Press, 2006, pp 507–548.
6.
Gish RG, Locarnini SA: Chronic hepatitis B: current testing strategies. Clin Gastroenterol Hepatol 2006;4:666–676.
7.
Wheeler CM: Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol 2007;4:224–235.
8.
Collins Y, Einstein MH, Gostout BS, Herzog TJ, Massad LS, Rader JS, et al: Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol 2006;102:552–562.
9.
Kundi M: New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007;6:133–140.
10.
Wagner PD, Verma M, Srivastava S: Challenges for biomarkers in cancer detection. Ann NY Acad Sci 2004;1022:9–16.
11.
O’Connell CD, Atha DH, Jakupciak JP: Standards for validation of cancer biomarkers. Cancer Biomark 2005;1:233–239.
12.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.
13.
Sherbenou DW, Druker BJ: Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007;117:2067–2074.
14.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817–2826.
15.
Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, et al: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 2006;98:1183–1192.
16.
Miller CR, McLeod HL: Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol 2007;5:9–14.
17.
Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, et al: Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007;4:e209.
18.
Brannon-Peppas L, Blanchette JO: Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649–1659.
19.
Vicent MJ, Duncan R: Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 2006;24:39–47.
20.
Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794–7803.
21.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205.
22.
Rodgers GM: Guidelines for the use of erythropoietic growth factors in patients with chemotherapy-induced anemia. Oncology 2006;20(suppl 6):12–15.
23.
Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Einsele H, et al: Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006;37:439–449.
24.
Torigian DA, Huang SS, Houseni M, Alavi A: Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin 2007;57:206–224.
25.
Sokolov K, Aaron J, Hsu B, Nida D, Gillenwater A, Follen M, et al: Optical systems for in vivo molecular imaging of cancer. Technol Cancer Res Treat 2003;2:491–504.
26.
Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR: American Society of Clinical Oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22:3631–3638.
27.
Jacobellis J, Martin L, Engel J, VanEenwyk J, Bradley LA, Kassim S, et al: Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing – Atlanta, Denver, Raleigh-Durham, and Seattle, 2003. MMWR Morb Mortal Wkly Rep 2004;53:603–606.
28.
Vadaparampil ST, Wideroff L, Olson L, Viswanath V, Freedman AN: Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility. Am J Med Genet A 2005;135:41–46.
29.
Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, et al: The research on adverse drug events and reports (RADAR) project. JAMA 2005;293:2131–2140.
30.
Ginsburg GS, Konstance RP, Allsbrook JS, Schulman KA: Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med 2005;165:2331–2336.
31.
Winn-Deen ES: Standards and controls for genetic testing. Cancer Biomark 2005;1:217–220.
32.
Burke W, Atkins D, Gwinn M, Guttmacher A, Haddow J, Lau J, et al: Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol 2002;156:311–318.
33.
Schoenhagen P: The role of coronary CT angiography (CTA) for patients presenting with acute chest pain: defining problem-specific, evidence-based indications of a novel imaging modality. Int J Cardiovasc Imaging 2007;23:429–432.
34.
Vaucher YE, Pretorius DH: Brain imaging in neonatal clinical trials: in search of a gold standard. J Pediatr 2007;150:575–577.
35.
Phillips KA, Van Bebber SL, Issa AM: Initial development of an evidence base for personalized medicine’s translation to clinical practice and health policy. Personalized Med 2006;3:411–414.
36.
Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J: Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care 2004;10:425–432.
37.
Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, et al: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant therapy. J Natl Cancer Inst 2007;99:196–205.
38.
Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, et al: Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the research on adverse drug events and reports (RADAR) project. Br J Haematol 2006;135:642–650.
39.
Lipscomb J, Donaldson MS, Hiatt RA, et al: Cancer outcomes research and the arenas of application. J Natl Cancer Inst Monogr 2004;33:1–7.
40.
Webster A, Martin P, Lewis G, Smart A: Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 2004;5:663–669.
41.
Constable S, Johnson MR, Pirmohamed M: Pharmacogenetics in clinical practice: considerations for testing. Expert Rev Mol Diagn 2006;6:193–205.
42.
Dervieux T, Bala MV: Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics 2006;7:1175–1184.
43.
Hiatt RA, Rimer BK: A new strategy for cancer control research. Cancer Epidemiol Biomarkers Prev 1999;8:957–964.
44.
Guttmacher AE, Porteous ME, McInerney JD: Educating health-care professionals about genetics and genomics. Nat Rev Genet 2007;8:151–157.
45.
McInerney J:Education in a genomics world. J Med Philos 2002;27:369–390.
46.
Penchansky R, Thomas JW: The concept of access: definition and relationship to consumer satisfaction. Med Care 1981;19:127–140.
47.
McLaughlin CG, Wyszewianski L: Access to care: remembering old lessons. Health Serv Res 2002;37:1441–1443.
48.
Meropol NJ, Schulman KA: Cost of cancer care: issues and implications. J Clin Oncol 2007;25:180–186.
49.
Kim P: Cost of cancer care: the patient perspective. J Clin Oncol 2007;25:228–232.
50.
Kabe KL, Kolesar JM: Role of trastuzumab in adjuvant therapy for locally invasive breast cancer. Am J Health Syst Pharm 2006;63:527–533.
51.
Eng C, Iglehart D: Decision aids from genetics to treatment of breast cancer: long-term clinical utility or temporary solution? JAMA 2004;292:496–498.
52.
Salsberg E, Erikson C: The changing physician workforce landscape: implications for physical medicine and rehabilitation. Am J Phys Med Rehabil 2007;86:838–844.
53.
Armstrong K, Micco E, Carney A, Stopfer J, Putt M: Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 2005;293:1729–1736.
54.
Krieger N: Defining and investigating social disparities in cancer: critical issues. Cancer Causes Control 2005;16:5–14.
55.
Kilbourne AM, Switzer G, Hyman K, Crowley-Matoka M, Fine MJ: Advancing health disparities research within the health care system: a conceptual framework. Am J Public Health 2006;96:2113–2121.
56.
Hall MJ, Olopade OI: Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol 2006;24:2197–2203.
57.
Phillips KA, Veenstra D, Van Bebber S, Sakowski J: An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics 2003;4:231–239.
58.
Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2004;22:854–863.
59.
Goldie SJ, Levin AR: Genomics in medicine and public health: role of cost-effectiveness analysis. JAMA 2001;286:1637–1638.
60.
Goldie S: A public health approach to cervical cancer control: considerations of screening and vaccination strategies. Int J Gynaecol Obstet 2006;94(suppl 1):S95–S105.
61.
Wingo PA, Howe HL, Thun MJ, Ballard-Barbash R, Ward E, Brown ML, et al: A national framework for cancer surveillance in the United States. Cancer Causes Control 2005;16:151–170.
62.
Hiatt RA: The future of cancer surveillance. Cancer Causes Control 2006;17:639–646.
63.
Haux R: Health information systems – past, present, future. Int J Med Inform 2006;75:268–281.
64.
Lobach DF, Detmer DE: Research challenges for electronic health records. Am J Prev Med 2007;32:S104–S111.
65.
Deapen D: Cancer surveillance and information: balancing public health with privacy and confidentiality concerns (United States). Cancer Causes Control 2006;17:633–637.
66.
McDonald IG: Quality assurance and technology assessment: pieces of a larger puzzle. J Qual Clin Pract 2000;20:87–94.
67.
Sussman S, Valente TW, Rohrbach LA, Skara S, Pentz MA: Translation in the health professions: converting science into action. Eval Health Prof 2006;29:7–32.
68.
Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L: The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007;9:665–674.
69.
Col NF: The use of gene tests to detect hereditary predisposition to chronic disease: is cost-effectiveness analysis relevant? Med Decision Making 2003;23:441–448.
70.
Goldie SJ, Goldhaber-Fiebert JD, Garnett GP: Chapter 18: public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006;24(suppl 3):S155–S163.
71.
O’Sullivan AK, Thompson D, Drummond MF: Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value Health 2005; 8:67–79.
72.
Rogowski W: Current impact of gene technology on health care: a map of economic assessments. Health Policy 2007;80:340–357.
73.
Torti FM Jr, Reed SD, Schulman KA: Analytic considerations in economic evaluations of multinational cardiovascular clinical trials. Value Health 2006;9:281–291.
74.
Sellers TA, Caporaso N, Lapidus S, Petersen GM, Trent J: Opportunities and barriers in the age of team science: strategies for success. Cancer Causes Control 2006;17:229–237.
75.
McGuire DB: Building and maintaining an interdisciplinary research team. Alzheimer Dis Assoc Disord 1999;13(suppl 1):S17–S21.
76.
Halbert CH, Armstrong K, Gandy OH Jr, Shaker L: Racial differences in trust in health care providers. Arch Intern Med 2006;166:896–901.
77.
Corbie-Smith G, Thomas SB, St George DM: Distrust, race, and research. Arch Intern Med 2002;162:2458–2463.
78.
Shavers VL, Lynch CF, Burmeister LF: Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol 2002;12:248–256.
79.
Royal C, Baffoe-Bonnie A, Kittles R, Powell I, Bennett J, Hoke G, et al: Recruitment experience in the first phase of the African American hereditary prostate cancer (AAHPC) study. Ann Epidemiol 2000;10(8 suppl):S68–S77.
80.
Powell IJ: Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007;177:444–449.
81.
Hopkins MM, Ibarreta D, Gaisser S, Enzing CM, Ryan J, Martin PA, et al: Putting pharmacogenetics into practice. Nat Biotechnol 2006;24:403–410.
82.
Zerhouni EA: Research funding. NIH in the post-doubling era: realities and strategies. Science 2006;314:1088–1090.
83.
Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003;290:1624–1632.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.